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Biosynthetic Gene Cluster of the Glycopeptide
Antibiotic Teicoplanin: Characterization of Two
Glycosyltransferases and the Key Acyltransferase
glycopeptides characterized by the presence of a
unique long aliphatic chain attached to a sugar moiety
(Figure 1) [3]. This fatty acyl side chain is thought to be
derived from -oxidation of fatty acids [4]. In addition,
four minor components referred to as related sub-
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United Kingdom positions 1 and 3; a chlorine atom substituted on each of
the tyrosine residues; and three sugar moieties, N-fatty
acyl--D-glucosamine, N-acetyl--D-glucosamine, and
D-mannose at positions 4, 6, and 7, respectively.Summary
Particular attention has been drawn to the N-fatty
acyl--D-glucosamine substituent by the recent findingThe gene cluster encoding biosynthesis of the clini-
cally important glycopeptide antibiotic teicoplanin has that a semisynthetic glycopeptide, LY264826, has re-
markably increased activity owing to the chemical intro-been cloned from Actinoplanes teichomyceticus. Forty-
nine putative open reading frames (ORFs) were identi- duction of a hydrophobic moiety onto a sugar residue of
chloroeremomycin [6]. Alternative approaches to suchfied within an 89 kbp genetic locus and assigned
roles in teicoplanin biosynthesis, export, resistance, modification of glycopeptide antibiotics employ bio-
transformation techniques or genetically modified pro-and regulation. Two ORFs, designated orfs 1 and 10*,
showed significant homology to known glycosyltrans- ducer organisms to alter the structure of the target mole-
cule, as is commonplace for polyketide biosynthesisferases. When heterologously expressed in Esche-
richia coli, these glycosyltransferases were shown to [7, 8]. Our institute previously reported the first gene
cluster governing the formation of a glycopeptide, thatcatalyze the transfer of UDP-(N-acetyl)-glucosamine
onto, respectively, 3-chloro--hydroxytyrosine-6 (3-Cl- for chloroeremomycin [9]. This and subsequent reports
relating to the biosynthesis of balhimycin, complestatin,6Hty) and 4-hydroxyphenylglycine-4 (4Hpg) of the
teicoplanin heptapeptide aglycone. The product of an- A47934, and A40926 have greatly expanded our knowl-
edge of the biosynthesis of this important group of com-other ORF, orf11*, was demonstrated in vitro to trans-
fer n-acetyl-, n-butyryl-, and n-octanoyl-groups from pounds [10, 11, 12, 13]. Gene disruption or in vitro char-
acterization of genes heterologously expressed in E.acyl-CoA donors either to a free UDP-aminosugar or to
an aminosugar moiety in the teicoplanin pseudoagly- coli have further elucidated the steps involved in the
biosynthesis of these agents, and this has enabled thecone, thus identifying Orf11* as the key acyltransfer-
ase in teicoplanin maturation. These findings should generation of novel chimeric glycopeptides either
through the manipulation of biosynthetic pathways oraccelerate the combinatorial engineering of new and
improved glycopeptide drugs. through in vitro glycosylation of glycopeptide aglycones
or pseudoaglycones [14, 15, 16, 17]. These initial suc-
cesses have spurred us to obtain detailed informationIntroduction
relating to the biosynthesis of the clinically important
glycopeptide teicoplanin. Preliminary studies reportedTeicoplanin is one of only two glycopeptide antimicrobi-
als currently licensed for use in man. It is reserved for by others [18] had demonstrated that the genes for tei-
coplanin biosynthesis were clustered and lay within athe treatment of life-threatening infections caused by
100 kbp locus in A. teichomyceticus. As might be ex-gram-positive organisms, including methicillin-resistant
pected, the biosynthetic genes appeared to show ho-Staphylococcus aureus (MRSA) [1]. The rapidly escalat-
mology to genes responsible for glycopeptide biosyn-ing problem of antibiotic drug resistance has driven a
thesis in other published clusters.search for newer agents with superior efficacy against
We describe here the entire DNA sequence and identi-drug-resistant strains. Teicoplanin, however, remains an
fication of 49 genes involved in the biosynthesis of tei-extremely important agent for the treatment of severe
coplanin. As discussed below, the biosynthetic clustersepsis. It is considerably more potent than vancomycin
apparently includes all the genes needed for teicoplaninagainst gram-positive bacteria, has a lower toxicity, and
biosynthesis, regulation of biosynthesis, export, and re-a superior pharmacokinetic profile [2]. Teicoplanin for
sistance. We also describe the heterologous expressionclinical administration is a mixture of five teicoplanins
and enzymatic assay of two glycosyltransferases and(A2-1 to A2-5) produced by Actinoplanes teichomyceti-
of a candidate gene for the key fatty acyl transferase.cus, which are representative of a subgroup (type IV) of
The expressed gene products were found to be active,
enabling us to identify their respective roles in tei-*Correspondence: jbs20@cam.ac.uk (J.B.S.); sfh12@mole.bio.cam.
ac.uk (S.F.H.) coplanin maturation. The substrate flexibility shown by
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Figure 1. Structures of Teicoplanins
Teicoplanin for clinical administration is a mixture of five major teicoplanins (A2-1 to A2-5). Four minor components referred to as related
substances 1 to 4 (RS1–4) have also been isolated. The seven amino acids of teicoplanin from the N-terminal end to C-terminal end are
designated as AA-1 to AA-7, and the seven aromatic rings are lettered A thorugh G [3].
the fatty acyltransferase suggests real utility for this ure 2A). Likely functions for most of these could be
assigned by comparison of the predicted protein trans-enzyme in future combinatorial engineering of glycopep-
lation with gene products deposited in the publishedtide drugs.
sequence databases. These 49 genes are predicted to
be responsible for assembly of the antibiotic, resistance,
export, and regulation of synthesis. 35 orfs find homo-Results and Discussion
logs in other glycopeptide gene clusters (Table 1).
Biosynthesis of Nonproteinogenic Amino AcidsCloning and Sequencing of the tei Gene Cluster
Tyrosine and three nonproteinogenic amino acids, (S )-4-Approximately 500 cosmids from a genomic library of
hydroxyphenylglycine (Hpg), 3,5-dihydroxyphenylgly-A. teichomyceticus genomic DNA were randomly end
cine (Dpg), and -hydroxytyrosine (Hty), are used assequenced. The resulting DNA sequences were used to
building blocks in the teicoplanin group of glycopeptidesearch published protein databases using BLAST. Five
antibiotics. Chlorination of Tyr and Hty at amino acidcosmids were identified with a high degree of homology
positions 2 and 6 is proposed to occur at an early stageto genes previously identified in glycopeptide gene clus-
of synthesis prior to phenolic oxidative coupling, possi-ters. Four cosmids were sequenced in their entirety and
bly with tyrosine or Hty as the substrate [19]. Fourfound to encode genes consistent with biosynthesis of
enzyme-catalyzed steps have been identified in the bio-teicoplanin. The identification of genes involved in car-
synthesis of HPG in the chloroeremomycin producer A.bohydrate metabolism confirmed that the upstream limit
orientalis. These are designated prephenate dehydroge-of the cluster had been identified. The downstream limit
nase (Pdh), 4-hydroxymandelic acid synthase (HmaS),could not be identified. After PCR-based screening of
4-hydroxymandelic acid oxidase (HmO), and 4-hydroxy-
the library, a further clone was obtained that extended
phenylglycine aminotransferase (HpgT) [20, 21, 22]. Pdh
downstream of the sequenced locus. This clone was is commonly associated with the shikimate primary met-
also sequenced in its entirety and found to contain the abolic pathway and converts prephenate to 4-hydroxy-
downstream limit of the cluster, as shown by the pres- phenylpyruvate, the substrate for HmaS [23]. In addition
ence of insertion sequences and genes involved in man- to a Pdh homolog designated Orf24* in the tei cluster,
ganese transport. In total, 120 kbp of the teicoplanin Orf 14* is a homolog of a dual-function enzyme that
cluster and of the flanking sequences were isolated and possesses both 7-phospho-2-dehydro-3-deoxy-D-ara-
sequenced from A. teichomyceticus. binoheptulosonate synthetase (DAHPS) and chorismate
mutase activities [23]. The presence of these enzymes
in the tei cluster may reflect the high demand for tyrosine
Organization of the Teicoplanin Cluster (five out of seven amino acids in teicoplanin originate
The biosynthetic gene cluster of teicoplanin (tei) spans from tyrosine). Combining information from the tei and
cep clusters permits a detailed proposal to be made forapproximately 89 kbp and includes 49 putative orfs (Fig-
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Figure 2. Genetic Arrangement and Pro-
posed Gene Functions in the tei Cluster
(A) The designation of the tei cluster follows
conventional assignment for this class of an-
tibiotics, in which orf * indicates genes that
appear after NRPS. Each gene is represented
as an arrow bar that also indicates the relative
size of the gene and its transcriptional di-
rection.
(B) The four NRPSs in the tei cluster (TeiA–D)
house two, one, three, and one extension
modules, respectively. Comparison with other
previously described glycopeptide clusters re-
veals two different arrangements in which
seven modules are distributed between three
NRPSs in cep and bps clusters and between
four NRPSs in dbv, sta, com, and tei. †, mod-
ule 3 in ComB and StaB includes an extra
epimerization domain, but the domain in StaB
is proposed to be inactive; *, module 6 in
ComC includes an extra methylation domain
that is proposed to N-methylate residue 6 of
complestatin; X, all six clusters contain a de-
generate C or E domain adjacent to the end
TE domain.
the biosynthetic pathway to Hpg in A. teichomyceticus. Tyr in the presence of Fe2. This reaction requires one
equivalent of the cofactor tetrahydrobiopterin, which isThe first step involves the action of Orf14* followed by
other shikimate pathway enzymes to produce choris- produced from dihydrobiopterin by dihydrofolate reduc-
tase at the expense of one equivalent of NADPH [24].mate. Orf14* converts the chorismate into prephenate,
which undergoes a subsequent decarboxylation by In Tyr synthesis, a pivotal enzyme, GTP cyclohydrolase I,
hydrolyzes GTP into 7,8-dihydroneopterin triphosphate,Orf24* (Pdh) to generate 4-hydroxyphenylpyruvate. The
remaining steps are likely to be identical to those bio- the precursor to tetrahydrobiopterin. Therefore, we sug-
gest that Orf25*, Orf22*, and Orf4 together help to meetchemically characterized in the cep cluster. Orf28*
(HmaS) catalyzes the formation of (S )-4-hydroxymande- the high demand for Tyr, which serves not only as an
amino donor but also as a substrate for Tyr -hydroxy-late from 4-hydroxyphenylpyruvate. The (S )-4-hydroxy-
mandelate is subsequently oxidized by Orf29* (HmO, a lase (see below).
Dpg biosynthesis has also been studied in the glyco-flavin-dependent oxidase) to 4-hydroxyphenylglyoxy-
late, followed by transamination catalyzed by Orf23* peptide producers A. orientalis and A. mediterranei [25,
26, 27]. Four ORFs (DpgA–D) organized into a putative(HpgT, a pyridoxal phosphate-dependent transaminase)
using tyrosine as the amino donor to produce Hpg. The transcriptional unit together with one additional ORF
(HpgT) governing a transamination step have beendeaminated Tyr can directly serve as a substrate for
HmaS in the next catalytic cycle. shown to be involved in DPG production by the in vitro
characterization of biological activities [28]. The equiva-Three ORFs have inferred products with homology,
respectively, to phenylalanine hydroxylase (PAH, a non- lent genes encoding these enzymes in A. teichomyceti-
cus are designated Orfs 17*–20* and are organized ashaem dioxygenase) (Orf25*), dihydrofolate reductase
(Orf4), and GTP cyclohydrolase I (Orf22*). These three found in other published glycopeptide clusters. The syn-
thesis of -Hty from Tyr in balhimycin and chloroeremo-enzymes might represent an alternative route of tyrosine
biosynthesis in which phenylalanine is hydroxylated to mycin biosynthesis appears to follow a novel mecha-
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Table 1. Summary of Genes Identified from the tei Cluster
Related Clustersa Best Matchb
tei orfs cep bal com sta dbv Sourced Entrye Proposed Functionc
11R - - - - - Streptomyces coelicolor Q9XA73 Transcriptional regulator
10R - - - - - Streptomyces avermitilis Q82PM0 Transcriptional regulator
9 - - - - - Streptomyces coelicolor Q9L0G1 Short chain dehydrogenase
8 ? - - MurF - Streptomyces toyocaensis O33804 MurF; D-Ala- D-Ala adding enzyme
7 ? - - VanHst - Amycolatopsis orientalis Q9Z6H3 D-lactate dehydrogenase
6 ? - - VanAst - Streptomyces coelicolor Q9XAK7 D-Ala- D-Lac ligase
5 ? - - VanXst - Streptomyces toyocaensis Q9ZI81 D-Ala- D-Ala dipeptidase
4R - - - - - Vibrio vulnificus Q8D590 Dihydrofolate reductase
3R ? - - VanSst - Streptomyces toyocaensis Q8KLL0 Transcriptional regulator
2R ? - - VanRst - Streptomyces coelicolor Q8CJW1 Two component response regulator
1 GtfA BgtfA - - 9 Amycolatopsis orientalis P96559 Glycosyltransferase
A A BpsA A A 25 Streptomyces toyocaensis Q8KLL3 Peptide synthetase; module 1-2
B A BpsA B B 26 Streptomyces toyocaensis Q8KLL4 Peptide synthetase; module 3
C B BpsB C C 17 Streptomyces toyocaensis Q8KLL5 Peptide synthetase; module 4-6
D C BpsC D D 16 Amycolatopsis orientalis O52821 Peptide synthetase; module 7
1* 6 1 E E 15 Nonomuraea, ATCC39727 CAD91210 Unknown
2* 15 2 - ? 21 Amycolatopsis orientalis O52804 Hypothetical protein
3* - - - - 20 Nonomuraea, ATCC39727 CAD91215 Mannossyltransferase
4* 2 ? L U 24 Amycolatopsis orientalis O52818 ABC transporter
5* 7 OxyA I F 14 Streptomyces toyocaensis Q8KLL7 P450 monooxygenase
6* - - - G 13 Streptomyces toyocaensis Q8KLL8 P450 monooxygenase
7* 8 OxyB J H 12 Nonomuraea, ATCC39727 CAD91207 P450 monooxygenase
8* 10 BhaA - I 10 Streptomyces toyocaensis Q8KLM0 Halogenase
9* 9 OxyC - J 11 Nonomuraea, ATCC39727 CAD91206 P450 monooxygenase
10* GtfB Bgtf - - 9 Amycolatopsis orientalis P96559 Glycosyltransferase
11* - - - - 8 Nonomuraea, ATCC39727 CAD91203 Acyltransferase
12* - - - M 28 Nonomuraea, ATCC39727 CAD91223 -hydroxylase
13* - - - - ? Streptomyces avermitilis Q82H77 Acyl-CoA synthase
14* 31 ? - ? ? Thermotoga maritima Q9WYH8 DAHPS/Chorismate mutase
15* - - - Q 4 Streptomyces toyocaensis Q8KLK0 Transcriptional regulator
16* - - - ? 3 Streptomyces avermitilis Q93HJ7 LuxR regulatory protein
17* DpgA DpgA - DpgA 31 Amycolatopsis mediterranei Q939X3 DpgA
18* DpgB DpgB - DpgB 32 Amycolatopsis mediterranei Q939X2 DpgB
19* DpgC DpgC - DpgC 33 Streptomyces toyocaensis Q8KLK7 DpgC
20* DpgD DpgD - DpgD 34 Streptomyces toyocaensis Q8KLK8 DpgD
21* ? 7 - ? 35 Amycolatopsis mediterranei Q939X8 Na-H antiporter
22* - - - ? ? Synechococcus elongatus Q8DJB8 GTP cyclohydrolase I
23* HpgT PgaT HpgT HpgT 37 Streptomyces toyocaensis Q8KLK4 HpgT
24* Pdh ? Pdh Pdh 5 Streptomyces toyocaensis Q8KLK3 Prephenate dehydrogenase
25*R - - - M 28 Streptomyces toyocaensis Q8KLM4 Nonhaem iron dioxygenase
26*R - - - - - Mycobacterium leprae Q9CD74 Hypothetic protein
27* - - - - - Streptomyces coelicolor Q9RJ78 Hypothetic protein
28* HmaS 5 HmaS HmaS 2 Amycolatopsis orientalis O52791 HmaS
29* HmaO 6 HmaO HmaO 1 Nonomuraea, ATCC39727 CAD91196 HmO
30* - - - - 36 Streptomyces fradiae Q54145 Type II thioesterase
31* - - - - - Streptomyces avermitilis Q82GU2 Transcriptional regulator
32*R - - - - - Streptomyces avermitilis Q82RX4 Transposase
33*R - - - - - Streptomyces coelicolor Q9RK03 Hypothetical protein
34* - - - - - Rhizobium loti Q983I7 Manganese ABC transporter
R, gene on opposite strand; -, clearly missing in cluster; ?, perhaps present (may not have been sequenced or published yet).
a Existence of a homolog in other related glycopeptide clusters. A dash denotes its absence.
b Best relevant match found by BLAST searches in Swiss-Prot/TrEMBL.
c Proposed function in the teicoplanin biosynthetic gene cluster.
d Organism origin of the best matching sequence.
e Accession number of the best matching sequence.
nism proposed for the biosynthesis of novobiocin and putative gene product (Orf12*) that contains motifs typi-
cal of nonhaem iron dioxygenases and has a homolognikkomycin, in which three enzyme-catalyzed steps are
required [29, 30]. Tyr is initially activated by the adenyla- in both the dbv and sta clusters. As previously suggested
[13], this enzyme might hydroxylate the C3 position oftion domain of a di-domain NRPS and is covalently teth-
ered to an adjacent PCP domain of the same NRPS. A Tyr. Another homolog of this enzyme is found in the
chloramphenicol cluster, in which -hydroxylated PheP450 hydroxylase subsequently oxidizes the tethered
Tyr at its  position. The modified Tyr is then released residue is present in the peptide backbone [31].
Assembly of the Heptapeptidefrom the NRPS by a thioesterase. However, no counter-
parts of these genes are found in the tei, dbv, and sta Synthesis of the teicoplanin heptapeptide backbone is
catalyzed by four nonribosomal peptide synthetasesgene clusters. Analysis of the tei gene cluster reveals a
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(NRPSs) designated TeiA–D. NRPSs are multifunctional Halogenation
enzymes with a characteristic modular organization. Teicoplanin has two chlorinated amino acids at posi-
Each module harbors the catalytic domains necessary tions 2 (3-Cl-Tyr) and 6 (3-Cl--Hty), and the putative
for activation, covalent tethering, and functional modifi- halogenase Orf8* is proposed to catalyze halogenation
cation of each monomer as well as for catalysis of pep- of both of these amino acids. Indeed, orf8* is homolo-
tide-bond formation. The number and order of these gous to bhaA in the bal cluster, which has been shown
domains within the enzyme is normally consistent with to chlorinate both Tyr/-Hty residues 2 and 6 [19]. The
the sequence and structure of the peptide product [32, specificity and the timing of halogenation remain to be
33, 34]. Organization of the domains for adenylation (A), determined in each case.
thiolation (T), condensation (C), epimerization (E), and Glycosylations and Acylation
thioesterase (TE) within the four proteins was identified of Teicoplanin Aglycone
through comparison with consensus sequences from The pattern of glycosylation of teicoplanin antibiotics is
the published databases. Extension modules are dis- central to their biological activity [43]. It has been shown
tributed 2-1-3-1 between the four NRPSs, as in the that specific glycosylation occurs after the formation of
A40926 (dbv) (type IV), A47934 (sta) (type III), and com- heptapeptide aglycone [44]. By analogy to previously
plestatin (com) (type V) biosynthetic clusters and in con- characterized clusters, three separate glycosyl trans-
trast to the 3-3-1 arrangement in the chloroeremomycin ferases should be required for the glycosylation of the
(cep) and balhimycin (bal) biosynthetic clusters (type I) teicoplanin aglycone. The translated amino acid se-
(Figure 2B). quences from orf1 and orf10* in the tei cluster show
The assignment of modules is also fully consistent significant sequence similarity to GtfA and GtfB en-
with the predicted amino acid specificities of the corre- coded by the cep cluster, which glycosylate residues 6
sponding A domains [35, 36]. As in all four previously and 4 of the chloroeremomycin aglycone, respectively.
reported sequences for glycopeptide NRPSs, module 1 We suspected therefore that Orf1 and Orf10* fulfilled
has no E domain, although the configuration of the analogous functions in the tei cluster. The roles of these
amino acid in this position is D rather than L (non-amino two putative glycosyltransferases were experimentally
acid 3,5 dichloro-4-hydroxybenzoylformate is the first tested as described below. A third glycosyltransferase
building block in com) [9, 10, 11, 12, 13]. A further stereo- with specificity for mannose is required to complete
chemical inconsistency is seen in the sequence analysis the glycosylation of teicoplanin. Orf3* in the tei cluster
of the sta cluster, where an extra E domain found in shows significant sequence similarity to many putative
module 3 is claimed to be functionally inactive [12]. All
integral membrane proteins. A gene encoding a similar
six glycopeptide NRPSs contain a degenerate domain
protein has been identified in the dbv cluster (orf20).
(either C or E) of obscure function flanking the terminal
Orf20 (dbv) has been convincingly shown [13] to containTE domain.
sequence motifs characteristic of authentic mannosyl-A small but highly conserved gene of unknown func-
transferases, and these are shared by tei Orf3* (data nottion, designated orf1* in the tei cluster, is found immedi-
shown).ately downstream of the terminal TE domain of the NRPS
Resistancein many NRPS gene clusters [9, 10, 11, 13]. Orf30*, a
The organization of genes conferring teicoplanin resis-homolog of type II thioesterases (TE II), is found only in
tance in the tei cluster is similar to that of glycopeptidethe tei and dbv clusters but not others. The gene product
resistance in vancomycin-resistant Enterococci (VRE)may be involved in reducing the mispriming of NRPSs
[45, 46]. orf7 is homologous to vanH (encoding a D-lactate[37]. A similar role has been proposed for TE II enzymes
dehydrogenase), orf6 is homologous to vanA (encodingin polyketide synthases [38].
D-Ala-D-lactate ligase), and orf5 to vanX (coded forCyclisation of the Linear Heptapeptide
D-Ala-D-Ala dipeptidase). Activation of the resistanceThe characteristic rigid concave shape of teicoplanin
genes in VRE requires a two-component regulatory sys-and other glycopeptide antibiotics [39] is conferred by
tem. A transmembrane sensory histidine protein kinase,intramolecular crosslinks generated by phenolic oxida-
VanS, senses and responds to environmental stimulitive coupling reactions. It has been possible, for several
and activates an intracellular DNA binding response reg-of the glycopeptide antibiotics, to relate each crosslink
ulator designated VanR [43, 45, 46]. The tei cluster con-to a corresponding gene encoding a cytochrome P450
tains homologs of vanR and vanS designated orf2 andoxygenase. A series of gene disruption studies in the
orf3. These two genes are adjacent to the vanH, A, andbalhimycin-producing strain have revealed the order of
X cluster, forming the most intact set of resistant genesthe regioselective couplings. OxyB is suggested to
in a glycopeptide-producing strain that parallels thoseprime the first reaction, coupling residues 4 and 6, OxyA
found in VRE, but differing from those of S. toyocaensis,then couples residues 2 and 4, and OxyC then forms a
where the genes are separated by 20 kb. This appearsC-C bond between residues 5 and 7 [40, 41, 42]. The
to provide additional direct evidence of resistance dis-tei cluster contains four such genes, namely orfs 5*, 6*,
semination between species. Two extra orfs are also7*, and 9*, as found in the sta and dbv clusters, consis-
probably linked with the resistance genes: orf8, encod-tent with the four crosslinks that are found in the corre-
ing a D-Ala-D-Ala ligase (MurF in the sat cluster), andsponding glycopeptides. From sequence comparisons,
orf9, a putative short chain dehydrogenase, are alsowe propose that Orfs 5*, 7*, and 9* are related to OxyA,
probably involved in cell wall biosynthesis. The dbv andOxyB, and OxyC (similarity/identity: 90/78, 80/72, and
bal clusters utilize a different resistance mechanism in84/74), respectively, and hence responsible for cross-
which a carboxypeptidases, VanY, is responsible (VanYlinking residues 2–4, 4–6, and 5–7. The remaining P450
hydrolyzes the terminal D-Ala residue of late peptidogly-enzyme, Orf 6*, is therefore a candidate to catalyze
crosslinking of residues 1–3. can precursors) [43, 47].
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Genes for Export and Regulation [MH] appearing at 10.8 and 13 min must arise from
either glucosaminoyl-3-Cl-6Hty pseudoaglycone (5),Biosynthesis of secondary metabolites is highly regu-
lated, is associated with specific stages of the Strepto- which may undergo deacylation from N-acetyl-gluco-
saminoyl-3-Cl-6Hty or glucosaminoyl-4Hpg pseudo-myces growth cycle, and particularly occurs during
stages of nutrient limitation and growth of aerial hyphae. aglycone (4), which may undergo deacylation from
N-acyl-glucosaminoyl-4Hpg. The fourth peak shown atGenes can be identified in the teicoplanin cluster that
are likely to perform important regulatory functions. 15 min with m/z 1360 [M  H] must be mannosyl-7Dpg
pseudoaglycone (6).As previously described, orfs 2 and 3 encode compo-
nents of a bacterial two-component sensor kinase sys- After incubation of purified recombinant Orf1 with
UDP-N-acetyl-glucosamine and teicoplanin aglycone,tems probably involved in regulation of expression of
the resistance determinants. the LC/MS trace of the assay mixture showed a new
prominent peak at 13.9 min (Figure 4, LC trace C). TheA second class of regulators, designated the luxR
family, is activated when bound to autoinducer mole- mass spectrum revealed that this peak has exactly the
expected mass [M  H]  1401 corresponding tocules such as N-(3-oxohexanoyl)-L-homoserine lactone
(OHHL). The “helix-turn-helix” DNA binding motif of N-acetyl-glucosaminoyl heptapeptide pseudoaglycone
and the unique isotope profile of a compound containingthese proteins is located in the C-terminal section of
the sequence [48]. orf16* encodes a protein of 818 amino two chlorine atoms (Figure 4, 2). Incubation with UDP-
glucosamine as an alternative substrate did not produceacids with end-to-end homology to many luxR class
regulators, particularly to those encountered in second- any further new peaks. The orf1 gene product is there-
fore revealed as a glycosyltransferase that transfersary metabolite biosynthetic clusters. In addition, orfs 15*
and 31* show similarities to gene products implicated UDP-N-acetyl-glucosamine to the C3 hydroxy of 3-Cl-
6Hty in the teicoplanin heptapeptide aglycone toin a regulatory role in bacterial species. orfs 10 and 11
also show a high similarity to known regulators. Their form (2).
The second GtfB-like glycosyltransferase in the teilocation at the edges of the cluster and lack of any
homologs to these genes in other clusters means that cluster, Orf10*, was therefore expected to transfer a
sugar to the 4Hpg residue of the teicoplanin aglycone.a regulatory role for these genes awaits further study.
orfs 1*, 2*, 26*, and 27* are similar to putative open In agreement with this, when purified recombinant
Orf10* was incubated with UDP-N-acetyl-glucosaminereading frames in published databases. No functional
data are available to characterize these genes, and their and teicoplanin aglycone, it resulted in the appearance
of a new peak at 11.5 min in the LC/MS trace, againfunction remains speculative.
orf 4* encodes a membrane-spanning ATP-depen- with m/z 1401, which did not match any of the reference
compounds, consistent with it being structure 3 (Figuredent export pump with close matches to other transport-
ers found in glycopeptide gene clusters. It is therefore 4, LC trace D). When instead recombinant Orf10* was
assayed with UDP-glucosamine, a different new peaklikely that this is responsible for the export of mature
teicoplanin from the cell. Orf21* is similar to a number was observed at 10.8 min in the LC/MS trace with m/z
1359, which is in excellent agreement with the referenceof ion transporters, and similar genes have been identi-
fied in other glycopeptide gene clusters. Its role is un- compound glucosaminoyl-4Hpg pseudoaglycone (4) at
10.7 min (data not shown). Therefore, Orf10* is a glyco-certain.
syltransferase transferring either UDP-glucosamine or
UDP-N-acetyl-glucosamine specifically onto the 4HPG
Heterologous Expression, Purification, and Assay of the teicoplanin aglycone. Whether UDP-glucosamine
of Putative Glycosyltransferases Orf1 and Orf10* or UDP-N-acetyl-glucosamine is the preferred substrate
By heterologous expression of these two predicted gly- in vivo remains to be determined (see also below).
cosyltransferases in E. coli, we aimed both to verify The fact that Orf1 and Orf10* glycosyltransferases
their involvement in the production of teicoplanin and can react independently with the teicoplanin aglycone
to assign them individual catalytic roles. In addition, distinguishes this system from chloroeremomycin bio-
knowledge of their substrate specificity would increase synthesis, where glycoyltransfer appears to be ordered,
their usefulness in future attempts to engineer hybrid with GtfB known to act first with residue 4 [15, 16].
maturation pathways to obtain novel glycopeptides [15, Our analysis suggests that Orf1 has higher activity than
16, 17]. Each enzyme was expressed in soluble form in Orf10* against the aglycone, meaning that glycosylation
E. coli and purified by Ni-NTA affinity chromatography, at residue 6 is faster than at residue 4, but detailed
as outlined in Experimental Procedures. kinetic studies will be needed to confirm this (the conver-
The enzymatic activity of Orf1 and Orf10* was moni- sion of teicoplanin aglycone to corresponding mono-
tored by incubation of the enzyme with teicoplanin (pseu- sugar aglycone catalyzed by Orf1 and Orf10 with UDP-
do)aglycones and analysis of the products by LC-MS. N-Acetyl-glucosamine present in the typical condition
Newly-formed peak(s) were compared with LC-MS of were 50% and 20%, respectively). When incubations
reference samples of partially hydrolyzed teicoplanin contained both Orf1 and Orf10*, a new peak correspond-
metabolites (Figures 3A and Figure 4, LC trace A). The ing to the disaccharide pseudoaglycone (7) appeared
identity of the peaks in the LC spectrum of the partially in the LC trace, unambiguously confirming the role of
hydrolyzed teicoplanins was deduced as follows. these two enzymes in the glycosylation of teicoplanin
The peak at 13.8 min with m/z 1401 [M  H] must be (Figure 4, LC trace E). The proposed reaction sequences
N-acetyl-glucosaminoyl-3-Cl-6Hty pseudoaglycone (2), catalyzed by Orf1 and 10* are summarized in Figure 3B.
since only one N-acetyl-glucosamine moiety is present Orf1 and Orf10* were also tested using the vancomy-
cin aglycone as substrate. However, after incubation noin teicoplanin. The two peaks both with m/z 1359
Biosynthesis of Teicoplanin
113
Figure 3. Structures of Reference Teicoplanins and of the Products of Coupled Enzymatic Reactions of Orf1, 10*, and 11*
(A) Products of partial hydrolysis of teicoplanin referred to in this study.
(B) The sequential enzymatic reactions of Orf1, 10*, and 11* are shown. Orf1 and Orf10* independently catalyze conversion of teicoplanin
aglycone into the corresponding pseudoaglycones (2 and 3), which can each be further converted by the second glycosyltransferase to 7.
Orf10* transfers a UDP-glucosamine to teicoplanin aglycone, forming 4, which can be acylated by Orf11* into 8 using butyryl-CoA or can be
converted by coupled action of Orf1 and Orf11* into 9 using octanoyl-CoA and UDP-N-Ac-glucosamine.
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new products were observed. This contrasts with the compound 9 (Figure 5A, right panel). Again, a control
activity of GtfB in the cep cluster and GtfE in the vanco- experiment without Orf11* did not lead to formation of
mycin cluster, in which both enzymes can transfer acti- this product.
vated sugar either to vancomycin or teicoplanin agly- To address whether the acylation occurs before or
cone, but GtfE with much greater efficiency than GtfB after sugar attachment to the teicoplanin aglycone, we
[15, 16, 17]. Sugar donor specificity appears to be added Orf11* to an assay containing only UDP-glucos-
stricter for Orf1, which can only utilize UDP-N-acetyl- amine and octanoyl-CoA as substrates. LC/MS analysis
glucosamine, while Orf10* catalyzes sugar transfer from clearly revealed a new peak (absent from a control lack-
UDP-glucosamine, UDP-N-acetyl-glucosamine, and UDP- ing Orf11*) with m/z 692 [M  H], which corresponds
glucose. GDP-mannose was also used to test whether to UDP-N-octanoyl-glucosamine (Figure 5B, LC trace a,
either enzyme could transfer mannosyl groups to the 10). This result showed that the acylation can occur with
teicoplanin (pseudo)aglycone, but (as expected) no re- a free activated sugar. Next, the enzymatically synthe-
action was observed. The lower substrate specificity of sized UDP-N-octanoyl-glucosamine was used to test
Orf10* suggests its potential use to add other NDP- the glycosylation activity of Orf10* on this N-acylated
activated sugars to produce novel teicoplanin deriva- substrate. In parallel, the acyltransferase activity of
tives. Orf11* was assayed using glucosaminoyl-4Hpg pseudo-
In the present work, mannosyl transfer was not exam- aglycone (prepared using Orf10*) and octanoyl-CoA as
ined directly, but our results are consistent with the view substrates. Remarkably, N-octanoyl-glucosaminoyl-4Hpg
that mannosyl transfer is likely to be a later step in pseudoaglycone (with m/z 1484 [MH]) was produced
biosynthesis [49]. in both assays (Figure 5C, 11). Evidently, the acylation
catalyzed by Orf11* may occur either before or after
the attachment of the aminosugar to the teicoplaninHeterologous Expression, Purification, and Assay
aglycone, and glycosyltransferase Orf10* can utilize asof Putative Acyltransferase Orf11*
acyl donors either UDP-N-octanoyl-, UDP-N-butyryl-, orThe superior pharmacokinetic profile of teicoplanin has
UDP-N-acetyl-glucosamine.been plausibly attributed to the hydrophobic aliphatic
Our demonstration that acyl-CoA species can serveside chain on the aminosugar attached to residue 4. An
in vitro as acyl donors for the N-acylation does not ex-acyltransferase (Orf23) found in the dbv cluster has been
clude the possibility that in vivo acyl-ACP species couldproposed to carry out this reaction [13], but there is no
be alternative or even preferred donors for this reaction.homolog of this gene in the tei cluster. On the other
We note that orf13* in the tei gene cluster, which hashand, tei orf11*, which is homologous to unassigned
no counterparts in other related gene clusters, appearsgene orf8 in the dbv cluster, is adjacent to glycosyltrans-
from sequence comparisons to encode an acyl-CoAferase gene orf10* and possibly cotranscribed with it,
synthase that may be involved in the ATP-dependentso we considered Orf11* an attractive candidate for the
ligation of a free long fatty acid chain with free CoASHacyltransferase catalyzing the key N-acylation of gluco-
[50], which lends some support to the notion that acyl-saminoyl-4Hpg pseudoaglycone.
CoA species are utilized as donors.Orf11* was expressed in E. coli as soluble protein,
If UDP-N-acetyl-glucosamine is the preferred sub-and the recombinant enzyme was purified by Ni-NTA
strate for Orf10* in vivo, then removal of the acetyl groupaffinity chromatography as detailed in Experimental
must precede attachment of the fatty acyl chain. WeProcedures. Its ability to transfer an acyl group to a
considered the possibility that Orf11* might behave asglucosaminoyl-4Hpg pseudoaglycone was assayed by
a bifunctional enzyme catalyzing this net transacylation,incubation together with teicoplanin aglycone, UDP-
since there appear to be no other deacylases presentglucosamine, and butyryl-CoA in the presence of Orf10*.
in the tei cluster. However, there was no observableA new peak was observed with m/z 1429 [M  H], and
deacylation activity (data not shown) when Orf11* wasa characteristic isotope profile was revealed in the LC
incubated either with free UDP-N-acetyl-glucosaminetrace corresponding to compound 8 (Figure 5A, left
or with N-acetyl-glucosaminoyl 4Hpg teicoplanin pseu-panel). Formation of this compound was not seen in
doaglycone (prepared from enzymatic product of Orf10*).the absence of Orf11* (only compound 4 was formed
Therefore, if in vivo acylation follows aminosugar attach-instead). Orf11* was thus revealed as an acyltransferase
ment, UDP-glucosamine may be the preferred substratewith the specificity expected of the long-sought N-acyl-
for Orf10*.transferase.
Whichever of these parallel pathways is followed, theIncubation of Orf11* in the presence of both Orf1 and
observed relaxed substrate specificities of the newlyOrf10* with teicoplanin aglycone and a different acyl
identified Orf11* acyltransferase enzyme and of thedonor, octanoyl-CoA, confirmed this conclusion. A new
Orf10* glycosyltransferase certainly suggest that theypeak was observed that eluted after teicoplanin agly-
should prove useful in future engineering of novel glyco-cone (indicating increased hydrophobicity) and with the
m/z 1688 [M  H] and characteristic isotope profile for peptide production.
Figure 4. LC Traces of Enzymatic Assays and Mass Spectra of Relevant Compounds
The LC traces and peaks shown are as follows. Trace A, partially hydrolyzed reference compounds; trace B, teicoplanin aglycone; trace C,
assay of Orf1; trace D, assay of Orf 10*; trace E, coupled assay of Orf1 and 10*. Compounds: 1, teicoplanin aglycone; 2, N-Ac-glucosaminoyl-
3-Cl-6Hty pseudoaglycone; 3, N-Ac-glucosaminoyl 4Hpg pseudoaglycone; 4, glucosaminoyl-4Hpg pseudoaglycone; 5, glucosaminoyl-3-Cl-
6Hty pseudoaglycone; 6, mannosyl-7Dpg pseudoaglycone; 7, disaccharide pseudoaglycone.
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sequenced utilizing pUC forward and reverse primers. The completeSignificance
sequence of the cosmid was obtained from assembly of the overlap-
ping Sau3AI fragments. The sequence was edited with SeqEd v1.0.3.Teicoplanin is one of only two glycopeptide antibiotics
The GAP 4 program (Staden) was employed for sequence assembly.
approved for clinical use. The tei cluster required for NRPS tei genes were discovered in three overlapping cosmids span-
its biosynthesis is the most comprehensive yet re- ning110 kb. Detailed sequence analysis confirmed that the bound-
ary of the cluster 5 to the NRPS modules had been cloned but notported for glycopeptide formation, with 49 ORFs, in-
the 3 boundary. It was therefore necessary to obtain a further cos-cluding several unique features, an organization of the
mid that extended further downstream of the cloned sequence.resistance genes that is wholly different from those
Based on the newly identified sequence, three primers, TE1: 5-AAGfound in other glycopeptide-producing organisms but
ACG ACG CGG ACG AAG GCG TCG GTG CA-3, TE2: 5-GAT GGC
closely related to the resistance genes in vancomycin- GAT GGA TCG GTC GGA GAT TAG CA-3, and TE3: 5-CTC TTC CGG
resistant enterococci (VRE), providing the clearest yet GGC CAT CGT GAT CTC CCA TG-3, were designed, synthesized
(QIAGEN), and used in PCR screening of the 6  96 colonies ofevidence of resistance transfer between species. Puri-
cosmid library. One cosmid that gave a positive PCR product wasfied recombinant enzymes from the tei cluster have
further subcloned and sequenced as above and was confirmed tobeen used to obtain direct evidence for the identity
extend beyond the downstream limit of the cluster A. The probableand role of Orfs 1 and 10* as glycosyltransferases
boundaries of the tei cluster were established by comparison with
catalyzing the transfer of UDP-(N-acetyl)-glucosamine other glycopeptide gene clusters and from the deduced functions
onto 3-Cl-6Hty and 4Hpg of teicoplanin heptapeptide of the tei and flanking gene products.
aglycone, respectively. Another gene product desig-
Characterization of Orf1, Orf10*, and Orf11*nated Orf11* has been identified by in vitro assay as
The orf1 was amplified from cosmid p3G10, and the orf10* and 11*the key N-acyltransferase that transfers a long fatty
genes were amplified from cosmid p4A7 by using PCR with theacid chain to a sugar moiety of teicoplainin pseudo-
following primers: orf1-p1, 5-GAA AAG GAT GTG CAT ATG CGC
aglycone, a modification which appears to markedly GTG CTG TTT-3; orf1-p2, 5-GCG GGC CCG GCG GAA TTC ACG
enhance glycopeptide activity. These and other tai- CGG GAA CCG-3; orf10*-p1, 5-TGG GGA TGC CAT ATG CGT GTG
TTG TTG TCG-3; orf10*-p2, 5-AGC CGG TGG AAT TCA CGC GGAloring genes and enzymes of the tei cluster can now
GAC CGA CGA-3; orf11*-p1, 5-CGT GAA CAT ATG ATG ATG GATbe deployed for the generation of new and improved
CCC GAG ACC-3; orf11*-p2, 5-CTC CGC GAA TTC TTA CGG CAGglycopeptide drugs.
CTT CAC GAA-3. The products were each ligated according to the
manufacturer’s instructions (Novagene) into expression vector pET-
Experimental Procedures 28a(), which provides an N-terminal His6-tagged protein. E. coli
cells were grown at 37C in 1 liter of LB medium until an A600 of
Isolation and Sequencing of the tei Cluster about 0.7 was reached. Protein expression was induced with 0.2 mM
Genomic DNA was isolated from Actinoplanes teichomyceticus IPTG at 16C, and after 12 hr cells were harvested by centrifugation,
DSM 43866 by “procedure B” of Hopwood et al [51]. Preparation resuspended in 10 mM imidazole-HCl buffer (pH 7.8) (binding buffer),
of a cosmid library of A. teichomyceticus chromosomal DNA in the and ruptured by sonification. The cell-free extract was applied to a
vector Supercos 1 was carried out according to manufacturer’s column of Ni2-NTA resin, which was then washed successively
instructions (Stratagene). Briefly, total DNA was partially digested with binding buffer and wash buffer (30 mM imidazole-HCl) before
with BamHI, dephosphorylated with shrimp intestinal alkaline phos- eluting the target protein with 100 mM imidazole-HCl. The buffer
phatase, and purified prior to ligation into Supercos 1 vector without was exchanged for 50 mM HEPES buffer (pH 7.2) using Millipore
size fractionation. The ligation mixture was packaged with Gigapack centrifugal filters. The relative molecular masses of purified proteins
III Gold Packaging Extract (Stratagene) followed by transfection into Orf1, Orf10*, and Orf11* were determined by electrospray mass
E. coli. XL1 Blue MR. Four hundred eighty individual colonies were spectrometry (ESI-MS) to be 43,227, 44,355, and 39,017 Da, respec-
inoculated into 1 ml of 2  LB medium with selection for ampicillin tively. The recombinant proteins are in good agreement with the
and kanamycin resistance and incubated at 37C overnight with predicted calculated masses, taking the His6 tag into consideration.
shaking in 5  96 well pates (ABgene). A 100 l aliquot of the grown Typical assays for the enzymes (10 g each) discussed in the
culture was preserved in 40% glycerol in 5  96 well plates (Orange text contained HEPES buffer (50 mM, pH 7.2), UDP-activated sugar
Scientific) and stored at 80C. Cosmid DNA was prepared using (2 mM), heptapeptide aglycone (2 mM), and coenzyme A derivative
High Yield Protocol 1 for plasmid minipreparation using MultiScreen (2 mM) in the presence of 1 mM MgCl2 and 1 mM DTT and were
(Millipore) and end sequenced with T3 and T7 primers. All sequenc- incubated (150 l final assay volume) for 2.5 hr at 25C. After incuba-
ing was performed using Big Dye Terminator kit in an ABI 373A tion, mixtures were centrifuged at 16,000  g for 5 min (Heraeus
sequencer according to the manufacturer’s protocols (ABI) in the Biofuge Pico) and then spun in an ultracentrifugal filter unit fitted
DNA Sequencing Facility of the Department of Biochemistry, Univer- with a 5 kDa cut-off membrane (Millipore). The resulting filtrate was
sity of Cambridge. Cosmids containing sequences with significant directly subjected to HPLC-ESI/MS analysis with a gradient solvent
similarity to related known biosynthetic genes of glycopeptide anti- system of increasing acetonitrile (0.1% TFA) in water (0.1% TFA)
biotics were identified using the BLAST algorithm and amplified in from 0 to 60% over 30 min. On-line LC-ESI/MS spectra were ob-
50 ml cultures from the stored glycerol deeps and DNA prepared tained from a Hewlett-Packard HPLC 1100 series instrument cou-
using Qiagen midiprep kits. These clones were subjected to partial pled to a Finnigan MAT LCQ ion trap mass spectrometer fitted with
a positive mode ESI source.digestion with Sau3AI, subcloned into pSHG397 plasmid [52], and
Figure 5. LC Traces of Assays Using Acyltransferase Orf11* and Mass Spectra of the Products
(A) LC traces and MS analysis of acylation products. Compounds: 8, N-Bu-glucosaminoyl-4Hpg pseudoaglycone; 9, N-octanoyl-glucosaminoyl-
4Hpg, N-acetyl-glucosaminoyl-3-Cl-6Hty pseudoaglycone.
(B) LC traces and MS analysis of UDP-glucosamine acylation catalyzed by Orf11*, in which traces a and b are assays in the presence or
absence, respectively, of Orf11* with UDP-glucosamine and octanoyl-CoA as substrates. Trace c is as for a, but with UDP-N-Ac-glucosamine
instead of UDP-glucosamine. Compounds: 10, UDP-N-octanoyl-glucosamine; u, unknown peak.
(C) LC traces and MS analysis of enzymatic assays catalyzed by Orf10* and Orf11*, respectively, in which traces a and b are assays
using as substrates UDP-N-octanoyl-glucosamine and N-Ac-glucosamine-4Hpg pseudoaglycone, respectively. Compound 11, N-octanoyl-
glucosamine-4Hpg pseudoaglycone, was produced in both assays.
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